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ABSTRACT
Periostin, an extracellular matrix protein belonging to the fasciclin family, has been shown to play a critical role
in the process of remodeling during tissueorgan development or repair. Periostin functions as a matricellular
protein in cell activation by binding to their receptors on cell surface, thereby exerting its biological activities. Af-
ter we found that periostin is a downstream molecule of interleukin (IL)-4 and IL-13, signature cytokines of type
2 immune responses, we showed that periostin is a component of subepithelial fibrosis in bronchial asthma, the
first formal proof that periostin is involved in allergic inflammation. Subsequently, a great deal of evidence has
accumulated demonstrating the significance of periostin in allergic inflammation. It is of note that in skin tissues,
periostin is critical for amplification and persistence of allergic inflammation by communicating between fibro-
blasts and keratinocytes. Furthermore, periostin has been applied to development of novel diagnostics or
therapeutic agents for allergic diseases. Serum periostin can reflect local production of periostin in inflamed le-
sions induced by Th2-type immune responses and also can predict the efficacy of Th2 antagonists against
bronchial asthma. Blocking the interaction between periostin and its receptor, αv integrin, or down-regulating
the periostin expression shows improvement of periostin-induced inflammation in mouse models or in in vitro
systems. It is hoped that diagnostics or therapeutic agents targeting periostin will be of practical use in the near
future.
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INTRODUCTION
A typical inflammatory response is composed of four
stages: 1) invasion by microbes or damage of tissues;
2) sensing infection or tissue damage by the immune
system; 3) production of mediators including cytoki-
nes, bioactive amines, and eicosanoids by the im-
mune system; and 4) effects of the mediators on tar-
get tissues.1 Once the invaded microbes are elimi-
nated or the damaged tissues are repaired, the in-
flammatory responses are terminated. However, if
the inflammatory response persists, a chronic inflam-
matory state will ensue. Chronic inflammatory re-
sponses often cause tissue changes including remod-
eling, fibrosis, and metaplasia, which lead not only to
the decline or loss of normal tissue functions, but also
to the onset of new clinical symptoms.1
Since allergic diseases such as bronchial asthma
and atopic dermatitis (AD) triggered by allergen inva-
sions usually become chronic, the affected lesions in
patients with these diseases present histologically
with chronic inflammation. Asthma patients show mu-
cus metaplasia, smooth-muscle hypertrophy, and en-
hanced deposits of subepithelial matrix proteins,
termed “airway remodeling”.2 These histological
changes are thought to lead to the airflow limitations
and airway hyper-responsiveness (AHR) found in
these patients. In AD patients, epidermal changes are
evident, including epidermal thickness called acan-
thosis and hyper-parakeratosis.3 Although the exact
pathological role of acanthosis remains unclear, we
speculate that it provides a basis for supplying mas-
sive proinflammatory mediators from keratino-
cytes.4,5
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Fig.　1　Two faces of periostin. Periostin has two faces: a conventional 
ECM protein (upper panel) and a matricellular protein (lower panel). As a 
conventional ECM protein, periostin is important for maintaining tissue/or-
gan structure or generating fi brosis, whereas it is important for cell activa-
tion as a matricellular protein. Periostin is composed of an EMI domain at 
the N terminus, four tandemly aligned FAS1 domains in the middle, and 
splicing domains at the C terminus. ECM proteins or a proteinase that can 
bind to the EMI domain or the FAS1 domains are depicted. In contrast, 
periostin binds to integrin molecules on cell surface transducing intracellu-
lar signals.
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Periostin, an extracellular matrix (ECM) protein,
has recently emerged as a novel mediator in chronic
states of allergic diseases and plays an important role
in tissue remodeling in allergic inflammation. In this
review article, we focus on the significance and clini-
cal application of periostin in allergic inflammation.
CHARACTERISTICS OF PERIOSTIN
Periostin, originally termed osteoblast-specific factor
2, is an ECM protein of 93.3 kDa in size.6 It belongs
to the fasciclin family on its homology to fasciclin 1
(FAS1). Periostin is composed of an EMI domain at
the N terminus, four tandemly aligned FAS1 domains
in the middle, and splicing domains at the C terminus
(Fig. 1). The EMI domain is able to bind to collagen I
and fibronectin,7-9 whereas the FAS1 domains can
bind to tenascin-C and bone morphogenetic protein
(BMP)-1.7,8,10 These abilities of periostin as an ECM
protein to interact extracellularly with other ECM
proteins or proteinase (BMP-1) are assumed to be
important in maintaining tissue structure or generat-
ing fibrosis.
Since periostin was first isolated from a mouse os-
teoblast cell line in 1993,11 our understanding of pe-
riostin biology began in osteology.6,12 It has turned
out that periostin contributes critically to bone devel-
opmentremodeling and bone strength. Expression
of periostin is up-regulated during fracture repair or
in response to mechanical stress when bone develop-
ment or remodeling is required. Periostin plays its
part by regulating collagen crosslinking and fibrillo-
genesis by binding to BMP-1 or by binding to Notch
1. Periostin biology has then been extended to the
field of cardiology.6,13 It has been shown that pe-
riostin plays a central role in cardiovascular differen-
tiation during in utero development of the cardiac
valves and fibrous heart skeleton. Even in the postna-
tal stage, when expression of periostin is low com-
pared to the embryonic stage, periostin expression is
rapidly up-regulated in response to insultinjury and
is involved in cardiac remodeling. Furthermore, we
and others recently showed that upon skin injury, pe-
riostin is transiently expressed in granulation tissues
and accelerates cutaneous wound repair.14-16 All of
these findings suggest that periostin is a “remodel-
ing” molecule. Thus the significance of periostin in
mesenchymal remodeling in various healthy and
pathological states has been established.
As periostin biology was becoming better under-
stood, it was revealed that periostin has another face,
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Fig.　2　Expression of periostin in asthma patients (cited from Ref. 32). The histochemical local-
ization of periostin in asthma patients is depicted. The left and right panels show bronchial tissues 
from an asthma patient in H&E staining (left panel) and in immunostaining of periostin (right pan-
el). Periostin in the right panel is stained in brown and is localized in the thickened basement 
membrane in asthma patients.
Periostin stainingH&E staining
Periostin Thickened basement membrane
as a type of ECM protein called a matricellular pro-
tein (Fig. 1). Matricellular proteins are defined as
ECM proteins binding to their receptors on cell sur-
face and functioning in cell activation rather than in
maintenance of tissue structure.13,17,18 Several in-
tegrins―such as αVβ1,19,20 αVβ3,20,21 αVβ5,20,21 α6β4,22
and αMβ223―have been reported to be periostin re-
ceptors. Binding of periostin with these integrin
molecules activates signal pathways, including
FAK,22,24 PI3-kinase,19,20,22,25 Akt,22,26 ERK,15 NF-
κB,4,14 and STAT3.15 Activating these signal pathways
is important for periostin to exert its biological activi-
ties as a remodeling molecule.
DISCOVERY OF PERIOSTIN AS A NOVEL
MEDIATOR IN BRONCHIAL ASTHMA
Periostin was discovered as a novel mediator in aller-
gic diseases in the course of elucidating the patho-
genesis of bronchial asthma. The significance of in-
terleukin (IL)-13, a type-2 cytokine, in the pathogene-
sis of bronchial asthma was established around 2000
based on analyses of model mice and of susceptible
genes of asthma.27,28 In particular, bronchial epithe-
lial cells are an important target for IL-13 to cause
AHR, a typical feature of asthma.29 To elucidate the
effects of IL-13 on human bronchial epithelial cells,
we comprehensively identified IL-13-inducible genes
using the DNA microarray method, finding that pe-
riostin is one of the highly expressed genes.30 The in-
duction of periostin by IL-13 is more than ten-fold by
quantitative PCR analysis, and IL-4 has the same abil-
ity to induce periostin as IL-13.
To investigate involvement of periostin in the
pathogenesis of bronchial asthma, we generated anti-
bodies against periostin and performed immunohisto-
chemical analyses.7,31 We found that periostin is de-
posited on the thickened basement membrane in
asthma patients (Fig. 2). It is known that subepithe-
lial fibrosis, a cardinal feature of bronchial asthma, is
thickening of the lamina reticularis, in which colla-
gens I, III, and V; fibronectin; and tenascin-C are de-
posited beneath the basal lamina (the “true” base-
ment membrane).32,33 The localization of periostin is
the same as that of these ECM proteins, suggesting
that periostin is a novel component of subepithelial fi-
brosis in bronchial asthma. Deposition of periostin
can be observed in the subepithelial areas of model
mice in an IL-4- or IL-13-dependent manner.7 Interest-
ingly, fibroblasts are likely to be the major source of
periostin, although we first found periostin as an IL-
13-inducible gene in airway bronchial epithelial cells.
Upon stimulation of IL-4 or IL-13, airway epithelial
cells express periostin at mRNA level, but not at pro-
tein level, whereas fibroblasts can secrete periostin
proteins. This was the first formal proof that periostin
is involved in bronchial asthma, and moreover in al-
lergic inflammation.
Subsequently, Fahy and colleagues in UCSF con-
firmed the up-regulated expression of periostin in
asthma patients.34,35 Importantly, asthma patients can
be classified into “Th2-high” and “Th2-low” asthma in
which expression of IL-13 and IL-5 is high and low,
respectively. Periostin is a signature molecule of
“Th2-high” asthma together with chloride channel
regulator 1 and serpin peptidase inhibitor, clade B,
member 2.35 This finding established the basis for
the application of periostin as a biomarker of Th2-
high asthma. The pathological role of periostin in
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Table　1　Periostin-involving infl ammatory diseases
Reference(s)
• Allergic diseases
Bronchial asthma 32, 33
Atopic dermatitis 4
IgG4-related sclerosing sialadenitis 38
Eosinophilic otitis media 39
Allergic rhinitis and chronic rhinosinusitis 40
• Non-allergic diseases
Idiopathic pulmonary fi brosis 43
Drug-induced pulmonary fi brosis 44
Scleroderma 45
Proliferative diabetic retinopathy 45, 46
Bone marrow fi brosis 48
asthma still remains controversial; several initial stud-
ies using periostin-deficient mice showed that pe-
riostin acts as a protective molecule against allergic
airway inflammation.36,37 However, Bentley et al. re-
cently reported that periostin accelerates allergic air-
way inflammation using periostin-deficient mice and
neutralizing antibodies against periostin (American
Thoracic Society International Conference 2013).
More studies are needed to elucidate whether pe-
riostin exerts a beneficial or deleterious effect on the
onset of bronchial asthma.
THE FUNCTIONAL ROLE OF PERIOSTIN IN
ALLERGIC INFLAMMATION
After we demonstrated periostin’s involvement in the
pathogenesis of bronchial asthma, we surveyed in-
flammatory diseases for potential involvement of pe-
riostin, finding that periostin is involved in other aller-
gic diseases such as AD,4 IgG4-related sclerosing
sialadenitis,38 eosinophilic otitis media,39 and allergic
rhinitis and chronic rhinosinusitis40 (Table 1). These
results are plausible considering that periostin is a
downstream molecule of IL-4 or IL-13, highly ex-
pressed cytokines in allergic diseases. Yamaguchi et
al. and Ohta et al. describe the involvement of pe-
riostin in dermatologic or otolaryngologic diseases in
the same issue of this journal.41,42 It is of note that we
also found involvement of periostin in non-allergic in-
flammatory diseases such as idiopathic or drug-
induced pulmonary fibrosis,43,44 scleroderma,45 prolif-
erative diabetic retinopathy46,47 and bone marrow fi-
brosis.48 Additionally, various malignant tissues show
high expression of periostin.49,50 Since it is known
that various factors other than IL-4 and IL-13―trans-
forming growth factor β 151 and 352, fibroblast growth
factor 1,53 angiotensin II,53 BMP-2,54 and platelet-
derived growth factor,55―can induce periostin ex-
pression, these or unknown factors may contribute to
up-regulated expression of periostin in non-allergic
inflammatory states.
Although, as we mentioned earlier, the role of pe-
riostin in the pathogenesis of bronchial asthma is still
unclear, we proposed how periostin exacerbates and
persists allergic inflammation in skin tissues based
on the analyses of periostin-deficient mouse and
three-dimensional organotypic coculture system us-
ing keratinocytes and fibroblasts (Fig. 3).4 Invasion of
allergens into hosts triggers type 2 immune re-
sponses. IL-4 and IL-13, type 2 cytokines, stimulate
production of periostin in fibroblasts. Periostin acts
on αv integrin on keratinocytes inducing production
of proinflammatory cytokines including TSLP. The
proinflammatory cytokines from keratinocytes then
amplify type 2 immune responses. Thus, IL-4IL-13,
periostin, and proinflammatory cytokines including
TSLP, compose a vicious circle in allergic skin inflam-
mation. This scheme shows that periostin plays a
critical role in amplification and persistence of aller-
gic inflammation by communicating between fibro-
blasts and keratinocytes. It is of note that fibrosis that
was believed before to be the end result of inflamma-
tion can be a platform for the onset of inflammation.
We then examined the molecular mechanism of
how periostin causes epidermal thickness (acantho-
sis) and hyper-parakeratosis in allergic skin inflam-
mation by extending the analyses using the three-
dimensional organotypic coculture system (Fig. 4).56
IL-1α is a cytokine secreted constitutively from kerati-
nocytes critical for proliferation and differentiation of
keratinocytes. Periostin secreted from fibroblasts
synergistically acts on fibroblasts with IL-1α inducing
production of IL-6 by activation of the NF-κB path-
way. IL-6 secreted from fibroblasts is another cy-
tokine critical for proliferation and differentiation of
keratinocytes. Thus, an autocrine loop of periostin is
involved in the regulation mechanism of keratinocyte
proliferation and differentiation, together with a
paracrine loop composed of IL-1α and IL-6. Periostin
would tune the magnitude of keratinocyte prolifera-
tion and differentiation by interacting with the
paracrine IL-1αIL-6 loop.
These findings demonstrate the significance of epi-
thelial cells and fibroblasts as targets of periostin in
allergic skin inflammation. Several reports support
this concept.14-16,25,44,47 Furthermore, periostin tar-
gets eosinophils, accelerating their adhesion to ECM
proteins.57 Thus, periostin plays an important role in
allergic inflammation by acting on epithelial cells, fi-
broblasts, eosinophils and possibly other undeter-
mined immune and non-immune cells.
USEFULNESS OF PERIOSTIN AS A BIO-
MARKER IN ALLERGIC DISEASES
Considering the findings that periostin is highly ex-
pressed in affected regions of various inflammatory
diseases, it is reasonable to assume that serum pe-
riostin is a biomarker reflecting local production of
periostin. Measurement of serum periostin has ad-
Periostin in Allergy
Allergology International Vol 63, No2, 2014 www.jsaweb.jp 147
Fig.　3　Vicious circle composed of IL-4/IL-13, periostin, and TSLP, in allergic skin infl am-
mation (modifi ed from Ref. 4). The vicious circle composed of IL-4/IL-13, periostin, and 
TSLP in allergic skin infl ammation is depicted. Invasion of allergens into hosts triggers 
type 2 immune responses. IL-4 and IL-13, type 2 cytokines, stimulate production of perios-
tin in fi broblasts. Periostin acts on αv integrin on keratinocytes inducing production of pro-
infl ammatory cytokines, including TSLP. The proinfl ammatory cytokines from keratinocytes 
then amplify type 2 immune responses.
Keratinocyte
Th2 cell
Allergen
FibroblastIL-4/IL-13
TSLP Periostin
Dv integrin
Vicious circle
Dendritic cell
Fig.　4　Molecular mechanism of epidermal thickness (acan-
thosis) and hyper-/parakeratosis by periostin in allergic skin 
infl ammation (modifi ed from Ref. 56). An autocrine loop of 
periostin and a paracrine loop composed of IL-1α and IL-6 
are involved in the regulatory mechanism of keratinocyte 
proliferation and differentiation. Periostin and IL-1α secreted 
from fi broblasts and keratinocytes, respectively, synergisti-
cally act on fi broblasts inducing production of IL-6 by activat-
ing the NF-κB pathway. IL-6 secreted from fi broblasts is criti-
cal for proliferation and differentiation of keratinocytes.
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IL-1D PeriostinIL-6
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NF-NB 
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vantages in being a biomarker for various inflamma-
tory diseases for two reasons. First, periostin is likely
to move easily from the affected lesions to vessels.
Second, since basal serum levels of periostin are rela-
tively low (~50 ngml) compared to other ECM pro-
teins such as fibronectin or vitronectin (200-300 μg
ml), up-regulated local production of periostin in the
affected lesions can be easily reflected to serum pe-
riostin levels. Thus far, several commercial or non-
commercial ELISA kits for periostin are available.
Since the detection limit in the ELISA kit that we de-
veloped is very low (~20 pgml), we can decrease the
effects of other serum proteins on the periostin analy-
sis using this kit.
Genentech developed serum periostin into a surro-
gate marker for Th2-high asthma based on the find-
ing that periostin is a signature molecule of Th2-high
asthma, which is characterized by higher AHR, se-
rum IgE, eosinophilic inflammation, subepithelial fi-
brosis, and epithelial mucins compared to Th2-low
asthma.35,58 Since IL-4 and IL-13 are critical mole-
cules for the onset of bronchial asthma in the model
mice, several antagonists against IL-13 andor IL-4
have been developed as anti-asthma agents; however,
some clinical trials have been disappointing or not
sufficiently satisfactory to continue the trials. One
reason why there is a discrepancy between the analy-
ses of model mice and the human trials is that as the
pathogenesis of asthma in humans is heterogenous
and diverse, it is important to cluster the asthma pa-
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Fig.　5　Novel algorithm for treatment of bronchial asthma pa-
tients. Inhaled corticosteroids (ICSs) are used as the fi rst line of 
anti-asthma drugs. If the patients are resistant to ICSs, serum 
periostin levels are measured for these patients to evaluate 
whether these patients are Th2-high or Th2-low patients. Then if 
they show high serum periostin levels, which means that they 
are Th2-high asthma patients, Th2 antagonists such as lebriki-
zumab or omalizumab are recommended for them. If not, other 
agents or treatments are recommended.
Asthma patients Inhaled corticosteroids
Measurement of 
serum periostin levels
Effective
Ineffective
High
LowOther agents
Th2 antagonists
tients based on their pathogenesis (endotypes) and to
evaluate the efficacy of drugs in each endotype. For
this reason, Genentech performed a phase IIa study
of anti-IL-13 antibodies (lebrikizumab) for steroid-
resistant asthma patients.59 In this trial, lebrikizumab
showed overall good efficacy in improving lung func-
tion for the patients. When the patients were divided
into high and low periostin groups based on serum
periostin levels, lebrikizumab showed significant effi-
cacy for the high periostin group, whereas it had no
efficacy for the low periostin group. Furthermore,
clustering asthma patients into these groups was also
useful for predicting the efficacy of anti-IgE antibod-
ies (omalizumab).60 From these findings, a novel al-
gorithm for treatment of asthma patients is proposed
as follows (Fig. 5): the first line of anti-asthma drugs
is inhaled corticosteroids (ICSs). Although ICSs are
effective for most patients, 5-10% are resistant to
it.61,62 By measuring serum periostin, the steroid re-
sistant patients can be grouped into Th2-high and
Th2-low patients. Then Th2 antagonists such as
lebrikizumab or omalizumab are recommended for
the Th2-high patients. This suggests that serum pe-
riostin can be a good biomarker to predict the effi-
cacy of biologics for asthma. Diagnostics useful for
prediction of efficacy of drugs are called “companion
diagnostic”. Periostin is the first example of compan-
ion diagnostics in the field of allergic diseases.
We also evaluated the usefulness of measurement
of serum periostin to treat asthma patients with
ICSs.63,64 The high serum periostin group is charac-
terized as asthma patients with late-onset, eosinophil-
dominant, and aspirin-intolerant asthma. We showed
that the high serum periostin group tended to be in-
sensitive to ICS or to have a risk of exacerbation after
tapering ICS doses. Matsumoto et al. describe the
usefulness of periostin in bronchial asthma in the
same issue of this journal.65 Taken together, these
findings show that periostin is a useful biomarker to
develop stratified medicine for bronchial asthma.
PERIOSTIN AS A PROMISING MOLECULAR
TARGET FOR DEVELOPING THERAPEUTIC
AGENTS AGAINST ALLERGIC DISEASES
As periostin plays an important role in the pathogene-
sis of allergic diseases, it is a promising molecular tar-
get for developing therapeutic agents against these
diseases. As we mentioned earlier, we showed that
periostin is critical for exacerbation and persistence
of allergic skin inflammation in model mice.4 In this
study, we evaluated the effects of neutralizing anti-
bodies against αv integrin, a functional receptor for
periostin, and applied these antibodies to two models:
preventive and therapeutic. In the preventive model,
when anti-αv integrin antibodies are administered to-
gether with allergens, AD-like phenotypes induced
by antigens are almost completely diminished. In the
therapeutic model, even when anti-αv integrin anti-
bodies are administered after AD-like phenotypes in-
duced by antigens are established, AD-like pheno-
types were decreased. These results indicate a possi-
bility that blocking a vicious circle including periostin
and αv integrin reversibly improves allergic skin in-
flammation, which demonstrates that periostin is a
promising molecular target for developing therapeu-
tic agents against these diseases.
There are two strategies to develop antagonists
against periostin (Fig. 6). The first strategy is to
Periostin in Allergy
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Fig.　6　Strategies to develop antagonists against periostin. One strategy to develop an-
tagonists against periostin is to search for a molecule to block the interaction between 
periostin and it receptors, integrin molecules (left panel). A second strategy is to search 
for a molecule to down-regulate the periostin expression (right panel).
z Inhibitor against the interaction with integrins z Therapeutic RNAi
Periostin protein 
Periostin mRNA 
siRNA
Periostin
Inhibitor Integrin
search a molecule to block the interaction between
periostin and its receptor, αv integrin. The second is
to search for a molecule to down-regulate periostin
expression. Anti-periostin neutralizing antibodies
aiming to block the interaction between periostin and
αv integrin have been developed.66 It has been as-
sumed that the YH sequence in the second FAS1 do-
main is the binding site for integrins, which may ex-
plain the ability of periostin to associate with integrin
molecules in spite of its lack of the RGD sequence.
These antibodies have shown therapeutic effects in a
mouse model of pulmonary fibrosis67 and bronchial
asthma (Bentley et al. American Thoracic Society In-
ternational Conference 2013). It is surprising that sys-
temic administration of the antibodies improves the
pathogenic phenotypes in spite of abundant expres-
sion of periostin in the whole bodies. An RNA inter-
ference (RNAi) method has been applied to down-
regulate the periostin expression and has had benefi-
cial effects on proliferative diabetic retinopathy45 and
progression of cancer cells.68,69 Although this strat-
egy involves problems in drug delivery, it is attractive
in that antagonists based on RNAi are sure to be
cheaper than biologics.
PERSPECTIVES
Increasing evidence has shown the significance of pe-
riostin as a novel mediator in allergic inflammation.
Periostin has a unique function as an inflammatory
mediator linking immune cells and resident cells in
inflamed lesions. Furthermore, advances have been
made in applying periostin to development of novel
diagnostics and therapeutic agents for allergic dis-
eases. Both the concept of a molecular mechanism in
which periostin is involved and the clinical application
targeting periostin in allergic inflammation can be ex-
tended to other inflammatory diseases, malignancies,
and developmental biology because periostin acts as
a remodeling molecule in a wide variety of healthy
and pathologic states.
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